Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1/2 4Phase 1 4Phase 3 3Phase 4 1

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Solid Tumor 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Interventional × ensartinib × Clear all
NCT04837716 2026-02-19

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
12 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02959619 2023-08-21

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Betta Pharmaceuticals Co., Ltd.

Phase 1 Completed
48 enrolled
Other solid neoplasmThoracic

Solid Tumor

NCT03510611 2019-07-24

A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.

Betta Pharmaceuticals Co., Ltd.

Phase 1 Completed
24 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03536481 2019-07-24

Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers

Betta Pharmaceuticals Co., Ltd.

Phase 1 Completed
74 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡